Open access
Open access
Powered by Google Translator Translator

Onco-hematology

Preliminary study suggests chemotherapy delivery in the afternoon may improve outcomes in patients with DLBC lymphoma

1 Feb, 2023 | 13:27h | UTC

Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma – JCI Insight

Commentaries:

Receiving Chemotherapy in the Afternoon May Improve Treatment Outcomes in Some Patients With DLBCL – The ASCO Post

Chemotherapy schedule affects treatment outcomes in female DLBCL patients – News Medical

 


Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant

30 Jan, 2023 | 00:23h | UTC

Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post

 

Commentary on Twitter

 


Post-trial follow-up | Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in early-stage unfavorable Hodgkin Lymphoma

27 Jan, 2023 | 11:58h | UTC

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial – Journal of Clinical Oncology

Commentaries:

NIVAHL Trial: Nivolumab and AVD Show Favorable Long-Term Safety and Efficacy in Early-Stage Unfavorable Classical Hodgkin Lymphoma – ASCO Daily News

Concomitant and Sequential Nivolumab, Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of German Hodgkin Study Group NIVAHL Trial – The ASCO Post

Original Study: Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial – JAMA Oncology

 


2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis

24 Jan, 2023 | 14:29h | UTC

2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee – Journal of the American College of Cardiology

Key Points: 2023 ACC Expert Consensus on Cardiac Amyloidosis – American College of Cardiology

News Release: ACC Expert Consensus Decision Pathway Focuses on Diagnosis and Management of Cardiac Amyloidosis – American College of Cardiology

 

Commentary on Twitter

 


ASCO Guideline | Management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients

24 Jan, 2023 | 14:28h | UTC

Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update – Journal of Clinical Oncology

 


ESMO Guideline | Venous thromboembolism in cancer patients

15 Jan, 2023 | 20:21h | UTC

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology

Related:

Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers

NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

 


Development and validation of a clinical prediction model for the prediction of 5-year survival in Hodgkin Lymphoma

13 Jan, 2023 | 13:12h | UTC

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium – Journal of Clinical Oncology

Commentaries:

HoLISTIC Consortium Develops Reliable Predictive Model for 5-Year Survival in Classic Hodgkin Lymphoma – ASCO Daily News

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma – News Medical

 

Commentary from the author on Twitter (thread – click for more)

 


An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants

13 Jan, 2023 | 13:10h | UTC

News Release: An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants – American Association for Cancer Research

Original Article: Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting – Clinical Cancer Research

Commentary: Study Finds Posoleucel Demonstrated Antiviral Efficacy and Safety Against Viral Infections Following Allogeneic Stem Cell Transplantation – The ASCO Post

 


Phase 2 RCT | Upfront autologous HSCT vs. carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in multiple myeloma

12 Jan, 2023 | 12:56h | UTC

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial – The Lancet Haematology

Invited Commentary: Upfront autologous transplantation still improving outcomes in patients with multiple myeloma – The Lancet Haematology

 


Special Issue | American Society of Hematology Education Program (series of open-access review articles)

10 Jan, 2023 | 14:26h | UTC

Homepage: American Society of Hematology Education Program – Hematology

 


RCT | Zanubrutinib vs. Ibrutinib in relapsed or refractory chronic lymphocytic leukemia.

16 Dec, 2022 | 13:33h | UTC

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Zanubrutinib Found Superior to Ibrutinib for CLL and SLL – The ASCO Post

 


Single-arm P1 study | Talquetamab, a T-Cell–redirecting GPRC5D bispecific antibody for multiple myeloma.

12 Dec, 2022 | 12:38h | UTC

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: More Than 70% of Heavily Pretreated Patients Taking Talquetamab for Multiple Myeloma See Responses That “Deepen Over Time” – AJMC

 

Commentary on Twitter

 


Single-arm P1/2 study | Glofitamab for relapsed or refractory diffuse Large B-Cell Lymphoma.

12 Dec, 2022 | 12:37h | UTC

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Review | AL Amyloidosis for Cardiologists.

6 Dec, 2022 | 13:36h | UTC

AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 


Joint consensus statement on the vaccination of adult and pediatric hematopoietic stem cell transplant recipients.

30 Nov, 2022 | 13:39h | UTC

Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children’s cancer and Leukaemia Group (CCLG), and British Infection Association (BIA) – Journal of Infection

 


Consensus Paper | Hematopoietic cell transplantation in the management of myelodysplastic syndrome.

29 Nov, 2022 | 14:11h | UTC

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines – Transplantation and Cellular Therapy

 


Post-trial follow-up | OS with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma.

25 Nov, 2022 | 12:25h | UTC

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial – Journal of Clinical Oncology

Original Study: Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma – New England Journal of Medicine

 


RCT | Zanubrutinib vs. Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.

22 Nov, 2022 | 13:03h | UTC

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial – Journal of Clinical Oncology 

 


M-A | Prophylactic platelet transfusions vs. no prophylaxis in hospitalized patients with thrombocytopenia.

21 Nov, 2022 | 13:59h | UTC

Prophylactic platelet transfusions versus no prophylaxis in hospitalized patients with thrombocytopenia: A systematic review with meta-analysis – Transfusion 

 


Single-arm P1/2 study | Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma.

11 Nov, 2022 | 13:05h | UTC

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial – The Lancet Haematology (link to abstract – $ for full-text)

 

Commentaries on Twitter

 


RCT | Prophylactic tranexamic acid did not decrease bleeding in patients with hematologic malignancy.

10 Nov, 2022 | 13:36h | UTC

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial – Blood

Commentary: Tranexamic Acid (TXA) Prophylaxis in Patients with Hematologic Malignancies – Physician’s Weekly

 


RCT | Brentuximab Vedotin with chemotherapy in pediatric high-risk Hodgkin’s Lymphoma.

4 Nov, 2022 | 13:30h | UTC

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows – News Medical

 


Cohort Study | Prognostic value of FLT3-internal tandem duplication residual disease in AML.

3 Nov, 2022 | 13:36h | UTC

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia – Journal of Clinical Oncology

 


Post-trial follow-up | Updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

31 Oct, 2022 | 13:36h | UTC

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab – Blood

 

Commentary on Twitter

 


Case Report | Acquired Hemophilia A secondary to an immune checkpoint inhibitor.

31 Oct, 2022 | 13:34h | UTC

Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report – JTO Clinical and Research Reports

Commentary: Report Details Rare Case of Acquired Hemophilia A Secondary to Immune Checkpoint Inhibition

 


Stay Updated in Your Specialty

No spam, just news.